Vaccination is an effective way to mitigate the current pandemic of Coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 1 Here, we report two cases of bullous pemphigoid (BP) that occurred shortly after COVID-19 vaccination. Our first case was a 23-year-old man with previous eczema presenting pruritic and tense bullae on the bilateral upper limbs 1 day after receiving a third dose of inactivated COVID-19 vaccine (Changchun Institute of Biological Products Co., Ltd., Changchun, China), spreading over the entire body within 10 days (Figure 1A,B), without response at the site of the first two injections. Histology showed subepidermal blister formation and an inflammatory infiltrate mainly composed of eosinophils in the dermis and bulla cavity (Figure 1C,D). Direct immunofluorescence revealed linear IgG and C3 deposits at the epidermisÀdermis junction (Figure 1E,F). Indirect immunofluorescence analysis demonstrated a positive titer of 1:10 for antibasement membrane zone antibodies. Antibodies against BP

An acute diffuse pustular eruption occurred in a patient after secukinumab injection and then the clinical presentation has been related to streptococcus infection after it has been isolated from throat swabs. Pustulosisacuta generalisata was definitively diagnosed. Antibiotic treatment had a poor effect, but the response to glucocorticoids was better.